Our study enhances understanding of the functional, bioinformatic, immunogenicity, frequency, and clinical characteristics of reported reduced penetrance cancer gene variants, using TP53 as an example, and demonstrates how these features can be used to provide a foundation for prediction models to better identify reduced penetrance disease-causing variants as being distinct from benign or standard penetrance pathogenic variants. The gene discussed is TP53; the disease is cancer.